"versionIdentifier","uuid:ID","instanceType","id","rationale"
"2","1167614e-7c44-4209-9bfa-e1aa05244afd","StudyVersion","StudyVersion_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
